REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 151.07 Billion | 154.03 Billion | 142.8 Billion | 130.03 Billion | 131.55 Billion | 122.99 Billion |
| Cost of Revenue | 74.25 Billion | 72.31 Billion | 63.36 Billion | 57.44 Billion | 57.29 Billion | 54.46 Billion |
| Gross Profit | 76.81 Billion | 81.72 Billion | 79.43 Billion | 72.58 Billion | 74.26 Billion | 68.52 Billion |
| Operating Expenses | 75.04 Billion | 72.4 Billion | 76.39 Billion | 69.13 Billion | 66.36 Billion | 66.06 Billion |
| Selling, General and Administrative Expenses | 31.53 Billion | 36.84 Billion | 35.53 Billion | 33.1 Billion | 34.69 Billion | 31.63 Billion |
| Research and Development Expenses | 8.37 Billion | 6.7 Billion | 9.72 Billion | 6.58 Billion | 3.72 Billion | 6.69 Billion |
| Other Expenses | 34.95 Billion | 28.85 Billion | 31.13 Billion | 29.44 Billion | 27.94 Billion | 68.07 Million |
| Cost and Expenses | 149.3 Billion | 144.71 Billion | 139.75 Billion | 126.58 Billion | 123.65 Billion | 120.53 Billion |
| Operating Income | 4.03 Billion | 7.4 Billion | 5.73 Billion | 4.14 Billion | 7.89 Billion | 2.45 Billion |
| Interest Expense | - | 122.19 Million | 111.19 Million | 178.01 Million | 116.32 Million | 536.71 Million |
| Income Tax Expense | 448.59 Million | -539.76 Million | 307.51 Million | 523.26 Million | 1.89 Billion | -492.97 Million |
| Earnings before Tax | 4.03 Billion | 6.89 Billion | 5.84 Billion | 4.36 Billion | 7.83 Billion | 848.51 Million |
| Net Income | 3.58 Billion | 7.43 Billion | 5.53 Billion | 3.84 Billion | 5.94 Billion | 1.34 Billion |
| Earnings Per Share Basic | 195.38 | 414.51 | 305.44 | 225.75 | 287.64 | 79.41 |
| Earnings Per Share Diluted | 195.38 | 414.51 | 305.44 | 225.75 | 287.64 | 79.41 |
| Weighted Average Shares Outstanding | 18.34 Million | 17.75 Million | 17.71 Million | 17.02 Million | 17.19 Million | 16.91 Million |
| Weighted Average Shares Outstanding (Diluted) | 18.34 Million | 17.75 Million | 17.71 Million | 17.02 Million | 17.19 Million | 16.91 Million |
| Gross Margin | 0.51 | 0.53 | 0.56 | 0.56 | 0.56 | 0.56 |
| EBIT Margin | 0.04 | 0.08 | 0.07 | 0.07 | 0.10 | 0.05 |
| Profit Margin | 0.02 | 0.05 | 0.04 | 0.03 | 0.05 | 0.01 |
| EBITDA | 6.55 Billion | 8.98 Billion | 6.21 Billion | 9.04 Billion | 10.69 Billion | 4.32 Billion |
| Earnings Before Tax Margin | 0.03 | 0.05 | 0.04 | 0.03 | 0.06 | 0.02 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 35.68 Billion | 37.01 Billion | 38.85 Billion | 151.07 Billion | 37.44 Billion | 37.74 Billion |
| Cost of Revenue | 18.68 Billion | 18.56 Billion | 19.94 Billion | 74.25 Billion | 19.1 Billion | 17.34 Billion |
| Gross Profit | 17 Billion | 18.45 Billion | 18.91 Billion | 76.81 Billion | 18.33 Billion | 20.4 Billion |
| Operating Expenses | 17.06 Billion | 17.44 Billion | 17.27 Billion | 75.04 Billion | -18.24 Billion | -17.74 Billion |
| Selling, General and Administrative Expenses | 16.22 Billion | 16.18 Billion | 15.94 Billion | - | 19.06 Billion | 21.29 Billion |
| Research and Development Expenses | 662.57 Million | 947.98 Million | 1.08 Billion | - | 1.43 Billion | 3.58 Billion |
| Other Expenses | -182.69 Million | -307.27 Million | -244 Million | -981.05 Million | -37.31 Billion | -39.03 Billion |
| Cost and Expenses | 35.75 Billion | 36 Billion | 37.22 Billion | 149.3 Billion | 19.1 Billion | 17.34 Billion |
| Operating Income | -69.27 Million | 1 Billion | 1.63 Billion | 1.76 Billion | 87.05 Million | 2.65 Billion |
| Interest Expense | 2.41 Billion | 2.52 Billion | 48.24 Million | 195.52 Million | 63.7 Million | 20.02 Million |
| Income Tax Expense | -475.81 Million | 633.44 Million | -153.62 Million | 448.59 Million | -64.03 Million | 308.8 Million |
| Earnings before Tax | 441.09 Million | 1.34 Billion | -538.8 Million | 4.99 Billion | -164.95 Million | 2.97 Billion |
| Net Income | 659.64 Million | 326.16 Million | -989.35 Million | 3.58 Billion | -100.92 Million | 2.66 Billion |
| Earnings Per Share Basic | 35.97 | 17.78 | -53.94 | - | -5.50 | 149.13 |
| Earnings Per Share Diluted | 35.97 | 17.78 | -53.94 | - | -5.50 | 141.18 |
| Weighted Average Shares Outstanding | 18.34 Million | 18.34 Million | 18.34 Million | 18.34 Million | 18.34 Million | 17.75 Million |
| Weighted Average Shares Outstanding (Diluted) | 18.34 Million | 18.34 Million | 18.34 Million | 18.34 Million | 18.34 Million | 21.85 Million |
| Gross Margin | 0.48 | 0.50 | 0.49 | 0.51 | 0.49 | 0.54 |
| EBIT Margin | 0.01 | 0.06 | 0.07 | - | 0.49 | 0.54 |
| Profit Margin | 0.02 | 0.01 | -0.03 | 0.02 | -0.00 | 0.07 |
| EBITDA | 385.26 Million | 2.06 Billion | 2.71 Billion | - | 18.33 Billion | 20.4 Billion |
| Earnings Before Tax Margin | -0.00 | 0.03 | 0.04 | 0.01 | 0.00 | 0.07 |
001020
ZEVY
OPTIEMUS
600111
RPPINFRA
VIBEF